Eric D. Mortenson

868 total citations
8 papers, 656 citations indexed

About

Eric D. Mortenson is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eric D. Mortenson has authored 8 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Immunology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eric D. Mortenson's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Immunotherapy and Immune Responses (3 papers). Eric D. Mortenson is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Immunotherapy and Immune Responses (3 papers). Eric D. Mortenson collaborates with scholars based in United States, China and South Korea. Eric D. Mortenson's co-authors include Yang‐Xin Fu, Xuanming Yang, Olga Radkevich-Brown, Yang Wang, Zhujun Jiang, Shengdian Wang, Mark I. Greene, Liufu Deng, Husain Sattar and Yang Liu and has published in prestigious journals such as Cancer Cell, Clinical Cancer Research and Science Translational Medicine.

In The Last Decade

Eric D. Mortenson

8 papers receiving 646 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric D. Mortenson United States 6 489 303 213 115 100 8 656
Olga Radkevich-Brown United States 7 464 0.9× 330 1.1× 219 1.0× 127 1.1× 95 0.9× 8 636
Lekh N. Dahal United Kingdom 15 258 0.5× 409 1.3× 196 0.9× 203 1.8× 42 0.4× 32 675
E Holz Germany 5 284 0.6× 184 0.6× 194 0.9× 143 1.2× 55 0.6× 8 475
Magi Khalil United States 6 543 1.1× 624 2.1× 107 0.5× 111 1.0× 52 0.5× 6 787
Jane E. Willoughby United Kingdom 11 233 0.5× 412 1.4× 122 0.6× 146 1.3× 27 0.3× 12 581
Diane L. Rossi United States 9 291 0.6× 175 0.6× 222 1.0× 139 1.2× 45 0.5× 16 462
Ornella Cutaia Italy 13 573 1.2× 366 1.2× 84 0.4× 131 1.1× 376 3.8× 23 923
Cesare Magalotti Italy 7 346 0.7× 94 0.3× 243 1.1× 102 0.9× 43 0.4× 10 529
Nancy Whiting United States 10 463 0.9× 283 0.9× 230 1.1× 125 1.1× 53 0.5× 18 683
Lauryn R. Werner United States 9 263 0.5× 161 0.5× 79 0.4× 176 1.5× 80 0.8× 19 475

Countries citing papers authored by Eric D. Mortenson

Since Specialization
Citations

This map shows the geographic impact of Eric D. Mortenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric D. Mortenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric D. Mortenson more than expected).

Fields of papers citing papers by Eric D. Mortenson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric D. Mortenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric D. Mortenson. The network helps show where Eric D. Mortenson may publish in the future.

Co-authorship network of co-authors of Eric D. Mortenson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric D. Mortenson. A scholar is included among the top collaborators of Eric D. Mortenson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric D. Mortenson. Eric D. Mortenson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Mortenson, Eric D. & Yang‐Xin Fu. (2014). Anti-HER2/Neu passive-aggressive immunotherapy. OncoImmunology. 3(1). e27296–e27296. 3 indexed citations
2.
Song, Hyunkeun, Tae Oh Kim, Sun Young, et al.. (2014). Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. BMC Cancer. 14(1). 647–647. 17 indexed citations
3.
Nalle, Sam C., Heewon Kwak, Karen L. Edelblum, et al.. (2014). Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease. Science Translational Medicine. 6(243). 243ra87–243ra87. 44 indexed citations
4.
Mortenson, Eric D., et al.. (2013). Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells. Clinical Cancer Research. 19(6). 1476–1486. 51 indexed citations
5.
Mortenson, Eric D. & Yang‐Xin Fu. (2012). Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. Current Pathobiology Reports. 1(1). 37–42. 10 indexed citations
6.
Yang, Xuanming, et al.. (2012). Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses. Molecular Therapy. 21(1). 91–100. 94 indexed citations
7.
Yang, Xuanming, Eric D. Mortenson, & Yang‐Xin Fu. (2011). Targeting and utilizing primary tumors as live vaccines: changing strategies. Cellular and Molecular Immunology. 9(1). 20–26. 4 indexed citations
8.
Jiang, Zhujun, Eric D. Mortenson, Liufu Deng, et al.. (2010). The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity. Cancer Cell. 18(2). 160–170. 433 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026